Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SBA-15 + Oxa(FBP)2
- Development stage
- Preclinical
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
SBA-15 + Oxa(FBP)2 (also written as SBA-15|[Oxa(FBP)2]) is an academic research-stage nanoparticle-encapsulated drug delivery construct [31]. It consists of mesoporous silica nanoparticles (SBA-15) loaded with [Oxa(FBP)2], a platinum(IV) prodrug conjugate [31]. The prodrug [Oxa(FBP)2] features an oxaliplatin core axially coordinated to two flurbiprofen (an NSAID) ligands [31]. This design aims to combine the cytotoxic DNA-damaging effects of oxaliplatin with the anti-inflammatory, cyclooxygenase (COX)-inhibiting properties of flurbiprofen, while the SBA-15 nanoparticles provide sustained release and passive tumor targeting [31]. It has been investigated in vitro for its antiproliferative activity against various human breast cancer cell lines, including triple-negative breast cancer (TNBC) and ER/PR-positive lines [31].
- Other names
- SBA-15|[Oxa(FBP)2]
02
Targets
DNA
Beyond the preview
Go deeper on SBA-15 + Oxa(FBP)2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SBA-15 + Oxa(FBP)2.